ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-12-15

No results posted yet for this study

Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Conditions

Interventions

DRUG

Fenretinide

Intravenous administration

DRUG

Fenretinide

Intravenous administration

Sponsors & Collaborators

  • SciTech Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Ali Moiin, MD · SciTech Development, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-11
Primary Completion
2027-05-01
Completion
2028-10-01
FDA Drug
Yes

Countries

  • United States

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06922539 on ClinicalTrials.gov